id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2000-N-0606-0002,FDA,FDA-2000-N-0606,"Division of Neuropharmacological Drug Products (DNDP) Issues Paper for March 9, 2000 Meeting of the Psychopharmacological Drugs Advisory Committee Meeting on the Various Psychiatric and Behavioral Disturbances Associated with Dementia",Supporting & Related Material,Background Material,2009-04-29T04:00:00Z,2009,4,,,2024-10-22T19:11:27Z,,0,0,09000064804dd984
FDA-2000-N-0606-0001,FDA,FDA-2000-N-0606,"Memorandum Re FDA Advisory Committee Discussion of Drug Development
for Treating Psychiatric Disturbances Associated with Dementias",Other,Memorandum,2009-04-29T04:00:00Z,2009,4,2009-04-29T04:00:00Z,,2024-10-22T19:07:12Z,,0,0,09000064804dd986